Keeping you in the loop.
Update February 19, 2013
Dr. Boulad and Dr. Sadelain provided answers to your questions. They said the protocol is currently open until July 2014 and patients are still being enrolled. The timing of the results will depend on patient accrual numbers and the levels of gene expression that are seen. They hope these issues will both be solved by July 2014. If it moves forward, this therapy would be for all types of Beta-thalassemia major independent of the Beta-globin gene mutation. In order to start treating patients affected by Beta-thalassemia, all (or at least the majority) of patients would need to engraft with the gene and become transfusion independent without any major side effects. The next steps would be production of the vector in larger scale, FDA approval for the vector, and extending the trial to a Phase II study. Licensing the vector to a biotech company may be necessary to broaden access to this therapy, just as it is with any new medication, chemotherapy, or biologic agent.
As mentioned in the youtube video posted by Sharmin, it takes about $1million to prepare the vector for small number of patients. Licensing to a biotech compnay should bring the cost down.
Best of luck to everyone.